BR112023022496A2 - Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos - Google Patents

Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos

Info

Publication number
BR112023022496A2
BR112023022496A2 BR112023022496A BR112023022496A BR112023022496A2 BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2 BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2
Authority
BR
Brazil
Prior art keywords
preparation
heterocyclic compound
medicines
application
same
Prior art date
Application number
BR112023022496A
Other languages
English (en)
Portuguese (pt)
Inventor
Feng He
Guodong Cai
Huaide Dong
Weikang Tao
Xin Li
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of BR112023022496A2 publication Critical patent/BR112023022496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112023022496A 2021-05-24 2022-05-24 Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos BR112023022496A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN202110694022 2021-06-22
CN202110856289 2021-07-28
CN202210198679 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112023022496A2 true BR112023022496A2 (pt) 2024-01-16

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022496A BR112023022496A2 (pt) 2021-05-24 2022-05-24 Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos

Country Status (11)

Country Link
US (1) US20240287094A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349836A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519188A (cg-RX-API-DMAC7.html)
KR (1) KR20240012437A (cg-RX-API-DMAC7.html)
CN (1) CN117177971A (cg-RX-API-DMAC7.html)
AU (1) AU2022280845A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022496A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219858A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013890A (cg-RX-API-DMAC7.html)
TW (1) TWI926045B (cg-RX-API-DMAC7.html)
WO (1) WO2022247816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
KR20250103773A (ko) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
JP2026524090A (ja) 2023-06-08 2026-07-17 上海森▲輝▼医▲葯▼有限公司 ホルムアミド系化合物の製造方法
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1

Also Published As

Publication number Publication date
CA3219858A1 (en) 2022-12-01
KR20240012437A (ko) 2024-01-29
TWI926045B (zh) 2026-05-21
CN117177971A (zh) 2023-12-05
EP4349836A4 (en) 2024-10-30
EP4349836A1 (en) 2024-04-10
US20240287094A1 (en) 2024-08-29
WO2022247816A1 (zh) 2022-12-01
AU2022280845A1 (en) 2023-12-14
TW202313630A (zh) 2023-04-01
MX2023013890A (es) 2023-12-11
JP2024519188A (ja) 2024-05-08

Similar Documents

Publication Publication Date Title
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
UY28271A1 (es) Compuestos químicos
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112023000817A2 (pt) Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo